Secondary prevention measures in anaphylaxis patients: Data from the anaphylaxis registry

Kraft M, Knop MP, Renaudin JM, Scherer Hofmeier K, Pfoehler C, Bilo MB, Lang R, Treudler R, Wagner N, Spindler T, Hourihane JO, Maris I, Koehli A, Bauer A, Lange L, Mueller S, Papadopoulos NG, Wedi B, Moeser A, Ensina LF, Fernandez-Rivas M, Cichocka-Jarosz E, Christoff G, Garcia BE, Poziomkowska-Gesicka I, Cardona V, Mustakov TB, Rabe U, Mahler V, Grabenhenrich L, Doelle-Bierke S, Worm M, Gruenhagen J, Dalke M, Beyer K, Kroegel C, Fuchs T, Rueff F, Oppel E, Dickel H, Merk H, Hillen U, Lotz C, Rietschel E, Aurich S, Klimek L, Pfaar O, Reider N, Aberer W, Bogatu B, Riffelmann F, Kreft B, Nemat K, Kinaciyan T, Brehler R, Witte J, Hunzelmann N, Huseynow I, Bieber T, Schmid-Grendelmeier P, Brosi W, Nestoris S, Hawranek T, Bruns R, Lehmann S, Hansen G, Becker S, Krecke N, Santernus R, Varga E, Szepfalusi Z, Eng P, Eng P, Reese T, Polz M, Schweitzer-Krantz S, Rebmann H, Stichtenoth G, Theis S, Yildiz I, Gerstlauer M, Nordwig A, Neustaedter I, Stadlin C, Buecheler M, Volkmuth S, Fischer J, Henschel A, Plank-Habibi S, Schilling B, Kleinheinz A, Schaekel K, Manolaraki I, Xepapadaki P, Douladiris N, Manoussakis E, Kowalski M, Solarewicz-Madajek K, Koener-Rettberg C, Tsheiller S, Hartmann K, Kemen C, Prenzel F, Ebner C, Haak S, Gil Serrano J, Galvan Blasco P, Haemmerling S, Arroabarren E, Cabanes Higuero N, Vega Castro A, Buesing S, Klettke U, Virchow C, Christoff G, Jappe U, Jakob T, Straube H, Vogelberg C, Knoepfel F, Correard K, Tobin C, Rogala B, Montoro A, Brandes A, Muraro A, Buck T, Buesselberg J, Zimmermann N, Hernandez D, Minale P, Niederwimmer J, Zahel B, Fiocchi A, Reissig A, Horak F, Meller S, Eitelberger F, Ott H, Asero R, Hermann F, Zeidler S, Pistauer S, Geissler M, Tarczon I, Sole D, Guerzet Ayres Bastos P, Martins De Aquino B, Camelo-Nunes I, Cocco R, Plaza Martin A, Meister J, Hompes S, Stieglitz S (2019)

Publication Type: Journal article

Publication year: 2019

Journal

DOI: 10.1111/all.14069

Abstract

Background Patients with a history of anaphylaxis are at risk of future anaphylactic reactions. Thus, secondary prevention measures are recommended for these patients to prevent or attenuate the next reaction. Methods Data from the Anaphylaxis Registry were analyzed to identify secondary prevention measures offered to patients who experienced anaphylaxis. Our analysis included 7788 cases from 10 European countries and Brazil. Results The secondary prevention measures offered varied across the elicitors. A remarkable discrepancy was observed between prevention measures offered in specialized allergy centers (84% of patients were prescribed adrenaline autoinjectors following EAACI guidelines) and outside the centers: Here, EAACI guideline adherence was only 37%. In the multivariate analysis, the elicitor of the reaction, age of the patient, mastocytosis as comorbidity, severity of the reaction, and reimbursement/availability of the autoinjector influence physician's decision to prescribe one. Conclusions Based on the low implementation of guidelines concerning secondary prevention measures outside of specialized allergy centers, our findings highlight the importance of these specialized centers and the requirement of better education for primary healthcare and emergency physicians.

Involved external institutions

Charité - Universitätsmedizin Berlin Germany (DE) Complejo Hospitalario de Navarra - Hospital de Navarra Spain (ES) Vall d'Hebron University Hospital / Hospital Universitari Vall d'Hebron Spain (ES) Johanniter-Krankenhaus im Fläming Treuenbrietzen GmbH Germany (DE) Medical University Sofia / Медицински университет Bulgaria (BG) Universidad Complutense de Madrid (UCM) Spain (ES) Universitätsklinikum Freiburg Germany (DE) Klinikum St. Marien Amberg Germany (DE) Medizinische Hochschule Hannover (MHH) / Hannover Medical School Germany (DE) Paracelsus Medizinische Privatuniversität Austria (AT) Ludwig-Maximilians-Universität (LMU) Germany (DE) Universitätsklinikum Leipzig Germany (DE) Hochgebirgsklinik Davos Switzerland (CH) University College Cork (UCC) Ireland (IE) Jagiellonian University / Uniwersytet Jagielloński (UJ) Poland (PL) Universitätsklinikum Jena Germany (DE) Universität Basel Switzerland (CH) Technische Universität Dresden Germany (DE) National and Kapodistrian University of Athens Greece (GR) Azienda Ospedaliero Universitaria Ospedali Riuniti Ancona Italy (IT) Universitäts-Kinderspital Zürich Switzerland (CH) Universität des Saarlandes (UdS) Germany (DE) Federal University of São Paulo / Universidade Federal de São Paulo (UNIFESP) Brazil (BR) Pomeranian Medical University / Pomorski Uniwersytet Medyczny w Szczecinie (PMU) Poland (PL) Paul Ehrlich Institute / Paul-Ehrlich-Institut – Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel (PEI) Germany (DE)

How to cite

APA:

Kraft, M., Knop, M.P., Renaudin, J.-M., Scherer Hofmeier, K., Pfoehler, C., Bilo, M.B.,... Stieglitz, S. (2019). Secondary prevention measures in anaphylaxis patients: Data from the anaphylaxis registry. Allergy. https://doi.org/10.1111/all.14069

MLA:

Kraft, Magdalena, et al. "Secondary prevention measures in anaphylaxis patients: Data from the anaphylaxis registry." Allergy (2019).

BibTeX: Download